Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001567619-19-011852
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-22 16:55:23
Reporting Period:
2019-05-20
Accepted Time:
2019-05-22 16:55:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1636282 Aeglea Biotherapeutics Inc. AGLE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1532219 G. Anthony Quinn C/o Aeglea Biotherapeutics, Inc.
901 S. Mopac Expressway, Suite 250
Austin TX 78746
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-05-20 8,989 $6.56 304,135 No 4 P Direct
Common Stock Acquisiton 2019-05-21 13,794 $6.89 317,929 No 4 P Direct
Common Stock Acquisiton 2019-05-22 3,809 $6.86 321,738 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
Footnotes
  1. Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.39 to $6.73 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.
  2. Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.53 to $7.00 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.
  3. Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.69 to $7.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.